Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

v3.20.2
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss        
Sales $ 292,381 $ 281,691 $ 550,289 $ 1,072,070
Cost of Sales 70,047 83,207 132,602 419,292
Gross Margin 222,334 198,484 417,687 652,778
Operating expenses        
Sales and marketing 244,262 584,775 467,447 1,168,507
Research and development 410,507 886,060 763,770 1,702,583
General and administrative 858,410 1,199,938 1,986,920 2,041,631
Share-based compensation expense (Notes 11) 212,939 638,219 620,254 925,976
Amortization (Note 4) 23,504 69,314 47,008 138,628
Depreciation (Note 7) 16,119 27,059 34,231 51,029
Total operating expenses 1,765,741 3,405,365 3,919,630 6,028,354
Other (income) expenses        
Other expense 111,408 170,739 186,383 185,035
Other income (46,178) 0 (83,790) 0
Foreign exchange 18,985 5,064 30,162 (57,283)
Total other expenses (income) 84,215 175,803 132,755 127,752
Net (loss) and comprehensive (loss) for the period $ (1,627,622) $ (3,382,684) $ (3,634,698) $ (5,503,328)
Loss per share - basic and diluted $ (0.32) $ (0.87) $ (0.71) $ (1.42)
Weighted average number of shares outstanding - basic and diluted 5,126,834 3,872,428 5,126,834 3,865,573